Abstract
Fibromatoses are a heterogeneous group of benign proliferating fibroblasts and myofibroblasts which have a high predilection for recurrence and local invasion, especially deep fibromatoses or desmoid fibromatosis. 18F-FDG PET/CT, the workhorse of oncological imaging in nuclear medicine, can be employed to figure out the nature and aggressiveness of the lesions and various sites of involvement and to monitor treatment response to systemic therapies like tyrosine kinase inhibitors in case of deep or desmoid fibromatoses which is shown in the current research work.
Similar content being viewed by others
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References
Lacka DE, Nasierowska-Guttmejer A. Fibromatosis - immunohistochemical evaluation, differential diagnosis from gastrointestinal tumors, and other mesenchymal tumours. Prz Gastroenterol. 2019;14:79–85.
Walker EA, Petscavage JM, Brian PL, Logie CI, Montini KM, Murphey MD. Imaging features of superficial and deep fibromatoses in the adult population. Sarcoma. 2012;2012: 215810.
DeVita VT Jr, Lawrence TS, Rosenberg SA, et al. DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology, vol. 2, chapter 45, Lippincot Williams and Wilkins, 8th edition. 2008.
Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumour. Am J Surg. 1986;151:230–7.
Ganeshan D, Amini B, Nikolaidis P, Assing M, Vikram R. Current update on desmoid fibromatosis. J Comput Assist Tomogr. 2019;43:29–38.
Zhang Z, Shi J, Yang T, Liu T, Zhang K. Management of aggressive fibromatosis. Oncol Lett. 2021;21:43.
Li Destri G, Ferraro MJ, Calabrini M, Pennisi M, Magro G. Desmoid-type fibromatosis of the mesentery: report of a sporadic case with emphasis on differential diagnostic problems. Case Rep Med. 2014;2014:850180.
Abdalla S, Wilkinson M, Wilsher M, Uzkalnis A. An atypical presentation of small bowel obstruction and perforation secondary to sporadic synchronous intra-abdominal desmoid tumours. Int J Surg Case Rep. 2016;20:147–50.
Robbin MR, Murphey MD, Temple HT, Kransdorf MJ, Choi JJ. Imaging of musculoskeletal fibromatosis. Radiographics. 2001;21:585–600.
Xu H, Koo HJ, Lim S, Lee JW, Lee HN, Kim DK, et al. Desmoid-type fibromatosis of the thorax: CT, MRI, and FDG PET characteristics in a large series from a tertiary referral center. Medicine (Baltimore). 2015;94(38): e1547.
Winiarczyk N, Beam A, Aird G, Broski S. 18F-FDG PET/CT evaluation of desmoid fibromatosis. J Nucl Med. 2021;63:177–177.
Kumar SS, Rajeevan K, Devarajan E. Desmoid-type fibromatosis-clinical study of an uncommon disease. Indian J Surg Oncol. 2020;11:71–4.
Alshammari A, Ashkanani R, Alabsi S, Ghanem M. Gardner syndrome with extra and intra-abdominal desmoid tumors and adrenal involvement: PET/CT findings. Case Rep Mol Imaging Radionucl Ther. 2015;24:38–41.
Braschi-Amirfarzan M, Keraliya AR, Krajewski KM, Tirumani SH, Shinagare AB, Hornick JL, et al. Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics. 2016;36:767–82.
Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, Hohenberger P. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging. 2010;37:1876–82.
Souza FF, Fennessy FM, Yang Q, van den Abbeele AD. Case report. PET/CT appearance of desmoid tumour of the chest wall. Br J Radiol. 2010;83:e39-42.
Choi KA, An YY. Desmoid tumor of the chest wall mimicking recurrent breast cancer: multimodality imaging findings. Iran J Radiol. 2016;13: e31649.
Kawashima K, Hiramatsu K, Kato T, Fukaya M, Aoba T, Arimoto A, et al. A desmoid tumor with fluorodeoxyglucose accumulation arising from the anastomotic site of postoperative gastric cancer: a case report. J Med Case Rep. 2022;16:423.
Mizuno M, Kawaguchi Y, Kawanishi A, Kawashima Y, Maruno A, Ogawa M, et al. An intra-abdominal desmoid tumor, embedded in the pancreas, preoperatively diagnosed as an extragastric growing gastrointestinal stromal tumor. Case Rep Oncol. 2017;10:301–7.
Suzumura K, Kondo Y, Okada T, Iimuro Y, Kuroda N, Torii I, et al. A case of an intra-abdominal desmoid tumor with FDG uptake on PET. J Jpn Surg Assoc. 2014;75:573–8.
Makis W, Ciarallo A, Abikhzer G, Stern J, Laufer J. Desmoid tumour (aggressive fibromatosis) of the colon mimics malignancy on dual time-point 18F-FDG PET/CT imaging. Br J Radiol. 2012;85:e37-40.
Nishio J, Aoki M, Nabeshima K, Iwasaki H, Naito M. Imaging features of desmoid-type fibromatosis in the teres major muscle. In Vivo. 2013;27:555–9.
Kumar JN, Indirani M, Sampathirao N, Shelley S. Fibromatosis with aggressive demeanor: benign impersonator of malignancy. World J Nucl Med. 2020;20:121–4.
Thakore KJ, Hudson TM, Monson DK, Scheidt KA. Triple-phase bone scan findings in aggressive fibromatosis. Before and after radiation therapy. Clin Nucl Med. 1994;19:197–203.
Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP. Desmoid tumor showing intense uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41:508–9.
Friesenbichler J, Molcan A, Aigner R, Sadoghi P, Liegl-Atzwanger B, Maurer-Ertl W, et al. The role of somatostatin receptor scintigraphy on the diagnosis of desmoid tumors. ISRN Oncol. 2012;2012: 167545.
De Pas T, Bodei L, Pelosi G, De Braud F, Villa G, Capanna R, et al. Italian Sarcoma Group. Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. Br J Cancer. 2003;88:645–7.
Author information
Authors and Affiliations
Contributions
Srinivas Ananth Kumar participated in the study design, drafting of the manuscript, and data acquisition. Harmandeep Singh, Lileswar Kaman, Ritambhra Nada, and Bhagwant Rai Mittal participated in the study conception and design, manuscript revision, and approval of the final content of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Consent to Participate
The institutional review board of our institute approved this study, and the requirement to obtain informed consent was waived.
Conflict of Interest
Srinivas Ananth Kumar, Harmandeep Singh, Lileswar Kaman, Ritambhra Nada, and Bhagwant Rai Mittal declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kumar, S.A., Singh, H., Kaman, L. et al. Annotating the Role of 18F-FDG PET/CT in Fibromatoses: A Benign Masquerader of Malignancies—Is It Really an Advantageous Tool?. Nucl Med Mol Imaging 58, 140–146 (2024). https://doi.org/10.1007/s13139-024-00846-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-024-00846-5